CERAD – Centre for the Design and Synthesis of Molecularly Targeted Radiopharmaceuticals (NCBJ, Świerk)
A national research infrastructure for the design, production, and study of new radiopharmaceuticals, being built at the National Centre for Nuclear Research (NCBJ) in Świerk near Otwock. At the heart of the complex is a Cyclone 30 XP cyclotron manufactured by the Belgian company IBA, accelerating protons and alpha particles to an energy of 30 MeV and deuterons to 15 MeV – this allows the production of radionuclides (including zirconium-89, astatine-211, copper-67) previously not produced at NCBJ and poorly available in Poland. The project is being carried out by a consortium of six scientific institutions led by NCBJ, and the undertaking is co-financed from the Smart Growth Operational Programme (POIR). The cyclotron arrived in Świerk in December 2023; a three-storey laboratory complex is being built over more than 2,500 m². CERAD complements the production of isotopes from the MARIA reactor with the production of cyclotron radionuclides, giving Poland a unique facility combining both sources.
How it went
This record carries no outcome assessment on any of the four axes yet. The timeline and sources below show what is known about it; the assessment itself has not been made.
Timeline
- Original dateDec 2022
Change history
- Dec 2023status: in progressCyclone 30 XP cyclotron delivered to Świerk (December 2023); laboratory complex nearing completion. No source from 2024–2026 confirming the start of production.
- Dec 2023stage: commissioning
Significance
CERAD gives Poland its own cyclotron-based source of innovative radionuclides for oncological diagnostics and therapy (including zirconium-89, astatine-211, copper-67), which until now were not produced in the country or were difficult to access. Combined with the production of isotopes from the MARIA research reactor, this makes NCBJ in Świerk a unique centre combining reactor-based and cyclotron-based production of radioactive preparations. The infrastructure, entered on the Polish Roadmap for Research Infrastructures and co-financed from POIR, is intended to support the design of molecularly targeted radiopharmaceuticals – including preparations tailored to the needs of individual patients. Despite its value being below the PLN 500 million threshold, the undertaking is of strategic importance as a national research and medical infrastructure.
Sources 6 · 4 independent · 2 archived
Every fact on this card comes from the sources below. Next to each source – which fields it supports.
Independence is counted the same way the gate that admits a record counts it: subdomains and titles from one publisher are a single voice, Wikipedia is zero. That is why the number is lower than the number of links. Three is the minimum.
- [1]CERAD – Centrum Projektowania i Syntezy Radiofarmaceutyków Ukierunkowanych Molekularnie ↗archived ✓Narodowe Centrum Badań Jądrowych (NCBJ)CostOriginal date
CostWartość Projektu przewidziana jest na 147,8 mln zł z czego ok. 73,0 mln zł będzie stanowiło dofinansowanie z Programu Operacyjnego Inteligentny Rozwój
Original dateRealizacja Projektu nastąpi w okresie od 1 sierpnia 2017 r. do 31 grudnia 2022 r.
- Narodowe Centrum Badań Jądrowych (NCBJ)15 Dec 2023InvestorStatusStageStage historyDescription
InvestorKoordynatorem konsorcjum CERAD jest Narodowe Centrum Badań Jądrowych
Status · Stage history · LocationCały nowy kompleks laboratoryjny CERAD w Świerku jest już na ukończeniu
StageCyklotron Cyclone 30 XP w tym tygodniu dotarł do swego miejsca przeznaczenia
DescriptionW cyklotronie będą rozpędzane protony i cząstki alfa do energii 30 MeV oraz deuterony do energii 15 MeV
- Mapa Dotacji UE (mapadotacji.gov.pl)EU fundingFunding
EU fundingProject value 234 177 167,70 zł
EU funding · FundingCo-financing from the EU 80 706 082,24 zł
Fundingprogram Program Operacyjny Inteligentny Rozwój action 4.2. Rozwój nowoczesnej infrastruktury badawczej sektora nauki fund Europejski Fundusz Rozwoju Regionalnego perspective 2014 - 2020
- Narodowe Centrum Badań Jądrowych (NCBJ)
StrategicUpon project completion in 2024, NCBJ will be a unique center capable of producing radioisotopes both in the reactor and with the cyclotron.
- Nauka w Polsce (PAP)
- EJNMMI Radiopharmacy and Chemistry (Springer) – peer-reviewed; co-author R. Mikołajczak is NCBJ POLATOM, lead authors are external17 Feb 2026Status
StatusIn Warsaw, Poland, an IBA Cyclone® C30XP has recently been installed, which will start optimizing the α-beam to produce astatine during 2026.